Trial Profile
A retrospective study evaluating efficacy and safety of Apatinib plus Icotinib as second line or greater therapy in patients with advanced non small cell lung cancer.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 02 Jun 2017
Price :
$35
*
At a glance
- Drugs Icotinib (Primary) ; Rivoceranib (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- 02 Jun 2017 Results (Data cut off December 2016), presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
- 02 Jun 2017 New trial record